BioSpace News Archive

Grant from Gates Foundation funds manufacturing capacity expansion and platform technology research

Pharvaris N.V. announced the pricing of an underwritten offering of 11,125,000 of its ordinary shares at a price of $24.00 per share and to one investor, pre-funded warrants to purchase 1,375,000 ordinary shares at a price of $23.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant.

Syros Pharmaceuticals today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist.

Coya Therapeutics, Inc. announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock.

Danaher Corporation (NYSE:DHR) (“Danaher”) announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) (“Abcam”).

Stryker (NYSE:SYK) announced today that after 15 years of distinguished service, Dr. Srikant Datar has notified the Company that he will not stand for re-election at Stryker’s 2024 Annual Meeting of Shareholders, which is expected to be held on May 9, 2024.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans.

Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) today announced the presentation of data on the psychometric validity and reliability of SUDS as an outcome measure in assessing anxiety in SAD clinical trials at the 2023 American College of Neuropsychopharmacology Annual Meeting taking place December 3 – 6 in Tampa, Florida.

Precede Biosciences today announced that data from its platform were presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX.

Petauri Health, a purpose-built pharmaceutical services platform, announced that two highly regarded healthcare executives, William Fleming and James Robinson, have been elected as members of the company’s Board of Directors.